Infection

Bestatin trifluoroacetate is an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase, used for cancer research.

T-00127_HEV1 (Standard) is the analytical standard of T-00127_HEV1 (HY-108313). This product is intended for research and analytical applications. T-00127_HEV1 is a phosphatidylinositol 4-K_inase III beta (PI4KB) inhibitor with an IC₅₀ of 60 nM.

PD 131628 is an antimicrobial agent and active PD 131112 metabolite. PD 131628 is two- to four-fold more active than Ciprofloxacin (HY-B0356), inhibiting all strains of Staphylococcus aureus and Streptococcus pneumoniae. PD 131628 is very active against Neisseria spp., Haemophilus influenzae and Moraxella catarrhalis, with MIC₉₀s ranging from 0.004 to 0.008 mg/L.

HDM-IN-1 (Compound A4) is an inhibitor for fungal histone demethylase (HDM), that inhibits the H3K27me3 in Cryptococcus neoformans and in Candida auris with IC₅₀s of 134 and 12 nM. HDM-IN-1 exhibits inhibitory efficacy against C. neoformans and C. auris with MIC₈₀ of 0.5-2 μg/mL, through inhibition of the biofilm and capsule formation. HDM-IN-1 exhibits antifungal activity in ICR mouse model.

rac-TNT-i (rac-NPD3064) is the racomer of TNT-i (HY-157469). TNT-i is an inhibitor targeting M-Sec. TNT-i reversibly inhibits the formation of tunnel nanotubes (TNT) induced by M-Sec. TNT-i can reduce the production of wild-type HIV-1 in macrophages and T cells expressing M-Sec. TNT-i has low cytotoxicity towards macrophages and T cells. TNT-i can be used in studies related to HIV-1 infection.

Karalicin inhibits herpes simplex virus HSV-1, HSV-2, vaccinia virus, polio virus type I with the IC₅₀s (μg/mL) of 0.004, 0.008, 0.016 and 0.016.

Hynapene A inhibits Eimeria tenella with a MIC of 34.7 μM.

Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).

Selgantolimod (Standard) is the analytical standard of Selgantolimod (HY-109137). This product is intended for research and analytical applications. Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection.

3-Hydroxypropionyl-CoA is a metabolic intermediate and enzyme substrate/product that functions in multiple metabolic pathways. 3-Hydroxypropionyl-CoA serves as a substrate for 3-Hydroxypropionyl-CoA dehydratase (HY-E71752), a product of 3-hydroxypropionyl-CoA synthetase, and a hydrolysis substrate for Ehd3p. 3-Hydroxypropionyl-CoA participates in autotrophic CO₂ fixation, modified β-oxidation, and reverse hydration reactions. Accumulation of 3-Hydroxypropionyl-CoA inhibits fatty acid β-oxidation at the Fox2p site and induces metabolic toxicity. 3-Hydroxypropionyl-CoA can be used in studies of hematogenously disseminated candidiasis.

SARS-CoV-2-IN-117 (Compound C19) is a SARS-CoV-2 E protein inhibitor. SARS-CoV-2-IN-117 significantly inhibits SARS-CoV-2 E protein interaction with host ZO-1 PDZ2 domain. SARS-CoV-2-IN-117 has potent antiviral activity and significantly reduces viral replication. SARS-CoV-2-IN-117 can be used for COVID-19 research.

CDK9-IN-1 (Standard) is the analytical standard of CDK9-IN-1. This product is intended for research and analytical applications. CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

SARS-CoV-2 3CLpro-IN-38 is a 3CLpro inhibitor with an IC₅₀ of 0.34 μM against SARS-CoV-2 3CLpro and an IC₅₀ of 0.12 μM against MERS-CoV 3CLpro. SARS-CoV-2 3CLpro-IN-38 inhibits recombinant Cathepsin L with an IC₅₀ of 5.23 nM. SARS-CoV-2 3CLpro-IN-38 inhibits cysteine proteases essential for the replication of SARS-CoV-2 and MERS-CoV, suppresses host cysteine proteases involved in coronavirus entry, blocks viral entry, and inhibits viral replication. SARS-CoV-2 3CLpro-IN-38 can be used in the research of COVID-19.

GP-1681 is a Beraprost sodium (HY-13569A) analogue. GP-1681 can be used in the research of influenza A H5N1 infection.

LP-03 is an antibacterial agent with selective activity against Methicillin-resistant Staphylococcus aureus (MRSA). Its minimum inhibitory concentration (MIC) is 6.2 μM. LP-03 has an inhibitory effect on biofilm formation, but it is unable to effectively remove the formed biofilms. LP-03 can enhance membrane permeability, disrupt the membrane structure of MRSA cells, and does not cause significant membrane depolarization. LP-03 has no hemolytic toxicity and shows low mammalian cell toxicity. It can be used for research on MRSA infections.

Baciphelacin is mainly resistant to gram-positive bacteria and has the activity of inhibiting Newcastle disease virus and leukemia P-388 cells.

SrtA-IN-1 (Compound T10) is an inhibitor of Streptococcus pyogenes sortase A (SpSrtA), with an IC₅₀ value of 0.7 μM. SrtA-IN-1 can be used in the research of the anti-infection field.

TachypleginA can inhibit the motility of T. gondii by binding directly and covalently to C58 of TgMLC1，thereby causing a decrease in the activity of the parasite's myosin motor.

Cefteram pivoxil (Standard) is the analytical standard of Cefteram pivoxil. This product is intended for research and analytical applications. Cefteram pivoxil (Ro 19-5248), an orally active cephalosporin antibiotic, is used for bacterial infections.

Diethylcarbamazine citrate (Standard) is the analytical standard of Diethylcarbamazine citrate (HY-12642). This product is intended for research and analytical applications. Diethylcarbamazine citrate is an orally active microfilaricidal agent used originally in onchocerciasis and lymphatic filiariasis. Diethylcarbamazine citrate reduces eosinophil trafficking to the lung tissue and exerts anti-allergic effects. Diethylcarbamazine citrate reduces serum levels of leptin, TNF-α, IL-6, MCP-1, glucose, insulin, and triglycerides, and ameliorates insulin resistance without altering body, liver, or adipose tissue weights. Diethylcarbamazine citrate enhances reactive oxygen intermediate expression by polymorphonuclear neutrophils, increases lymphocyte proliferation, and inhibits actinomycetoma lesion development. Diethylcarbamazine citrate can be used for the researches of bronchial asthma, insulin resistance and infection.